האיחוד האירופי - איטלקית - EMA (European Medicines Agency)

pfizer europe ma eeig - sirolimus - graft rejection; kidney transplantation - immunosoppressori - rapamune è indicato per la profilassi del rigetto d'organo in pazienti adulti a basso-moderato rischio immunologico che ricevono un trapianto renale. si raccomanda di utilizzare rapamune inizialmente in combinazione con ciclosporina in microemulsione e corticosteroidi per 2 per 3 mesi. rapamune può essere continuato come terapia di mantenimento con corticosteroidi solo se la ciclosporina in microemulsione può essere progressivamente eliminata. rapamune è indicato per il trattamento di pazienti con sporadici linfangioleiomiomatosi con moderata malattia polmonare o di declino della funzione polmonare.

האיחוד האירופי - איטלקית - EMA (European Medicines Agency)

novartis europharm ltd - midostaurin - leukemia, myeloid, acute; mastocytosis - agenti antineoplastici - rydapt è indicato:in combinazione con standard di daunorubicina e citarabina induzione e alte dosi di citarabina chemioterapia di consolidamento, e per i pazienti in risposta completa seguita da rydapt singolo agente terapia di mantenimento, per i pazienti adulti con nuova diagnosi di leucemia mieloide acuta (aml) che sono positivo alla mutazione flt3 (vedere la sezione 4. 2);come monoterapia per il trattamento di pazienti adulti affetti da mastocitosi sistemica aggressiva (asm), mastocitosi sistemica associata una neoplasia ematologica (sm ahn), o mast cell leucemia (mcl).

האיחוד האירופי - איטלקית - EMA (European Medicines Agency)

hansa biopharma ab - imlifidase - desensitization, immunologic; kidney transplantation - immunosoppressori - idefirix is indicated for desensitisation treatment of highly sensitised adult kidney transplant patients with positive crossmatch against an available deceased donor. the use of idefirix should be reserved for patients unlikely to be transplanted under the available kidney allocation system including prioritisation programmes for highly sensitised patients.

האיחוד האירופי - איטלקית - EMA (European Medicines Agency)

celltrion healthcare hungary kft. - bevacizumab - colorectal neoplasms; breast neoplasms; ovarian neoplasms; fallopian tube neoplasms; peritoneal neoplasms; carcinoma, non-small-cell lung; carcinoma, renal cell; uterine cervical neoplasms - agenti antineoplastici - vegzelma in combination with fluoropyrimidine based chemotherapy is indicated for treatment of adult patients with metastatic carcinoma of the colon or rectum. vegzelma in combination with paclitaxel is indicated for first line treatment of adult patients with metastatic breast cancer. per ulteriori informazioni sullo stato del recettore del fattore di crescita epidermico umano 2 (her2), fare riferimento alla sezione 5. vegzelma in combination with capecitabine is indicated for first line treatment of adult patients with metastatic breast cancer in whom treatment with other chemotherapy options including taxanes or anthracyclines is not considered appropriate. patients who have received taxane and anthracycline containing regimens in the adjuvant setting within the last 12 months should be excluded from treatment with vegzelma in combination with capecitabine. per ulteriori informazioni sullo stato her2, fare riferimento alla sezione 5. vegzelma, in addition to platinum based chemotherapy, is indicated for first line treatment of adult patients with unresectable advanced, metastatic or recurrent non small cell lung cancer (nsclc) other than predominantly squamous cell histology. vegzelma, in combination with erlotinib, is indicated for first line treatment of adult patients with unresectable advanced, metastatic or recurrent nsclc with epidermal growth factor receptor (egfr) activating mutations (see section 5. vegzelma, in combination with interferon alfa 2a is indicated for first line treatment of adult patients with advanced and/or metastatic renal cell cancer. vegzelma, in combination with carboplatin and paclitaxel is indicated for the front line treatment of adult patients with advanced (international federation of gynecology and obstetrics (figo) stages iii b, iii c and iv) epithelial ovarian, fallopian tube, or primary peritoneal cancer (see section 5. vegzelma, in combination with carboplatin and gemcitabine or in combination with carboplatin and paclitaxel, is indicated for treatment of adult patients with first recurrence of platinum sensitive epithelial ovarian, fallopian tube or primary peritoneal cancer who have not received prior therapy with bevacizumab or other vascular endothelial growth factor (vegf) inhibitors or vegf receptor–targeted agents. vegzelma in combination with paclitaxel, topotecan, or pegylated liposomal doxorubicin is indicated for the treatment of adult patients with platinum resistant recurrent epithelial ovarian, fallopian tube, or primary peritoneal cancer who received no more than two prior chemotherapy regimens and who have not received prior therapy with bevacizumab or other vegf inhibitors or vegf receptor–targeted agents (see section 5. vegzelma, in combination with paclitaxel and cisplatin or, alternatively, paclitaxel and topotecan in patients who cannot receive platinum therapy, is indicated for the treatment of adult patients with persistent, recurrent, or metastatic carcinoma of the cervix (see section 5.

האיחוד האירופי - איטלקית - EMA (European Medicines Agency)

bristol-myers squibb pharma eeig - mavacamten - cardiomyopathy, hypertrophic - altri preparati cardiaci - treatment of symptomatic obstructive hypertrophic cardiomyopathy.

שווייץ - איטלקית - Swissmedic (Swiss Agency for Therapeutic Products)

iscador ag - viscum album (mali) recenti - soluzione iniettabile (s. c.) - extractum aquosum liquidum fermentatum 5 mg ex viscum album (mali) recens 1 mg corresp., lectina ex visco 50 ng, natrii chloridum, aqua q.s. ad solutionem pro 1 ml. - gemäss der anthroposophischen menschen- und naturerkenntnis als zusatzbehandlung zur verbesserung der lebensqualität und eventuell des krankheitsverlaufes bei malignen geschwulstkrankheiten, auch mit begleitenden störungen der blutbildenden organe, bei benignen geschwulstkrankheiten und nach operationen von malignen geschwülsten - antroposofici

שווייץ - איטלקית - Swissmedic (Swiss Agency for Therapeutic Products)

iscador ag - viscum album (mali) recenti - soluzione iniettabile (s. c.) - extractum aquosum liquidum fermentatum 10 mg ex viscum album (mali) recens 2 mg corresp., lectina ex visco 100 ng, natrii chloridum, aqua q.s. ad solutionem pro 1 ml. - gemäss der anthroposophischen menschen- und naturerkenntnis als zusatzbehandlung zur verbesserung der lebensqualität und eventuell des krankheitsverlaufes bei malignen geschwulstkrankheiten, auch mit begleitenden störungen der blutbildenden organe, bei benignen geschwulstkrankheiten und nach operationen von malignen geschwülsten - antroposofici

שווייץ - איטלקית - Swissmedic (Swiss Agency for Therapeutic Products)

iscador ag - viscum album (mali) recenti - soluzione iniettabile (s. c.) - extractum aquosum liquidum fermentatum 25 mg ex viscum album (mali) recens 5 mg corresp., lectina ex visco 250 ng, natrii chloridum, aqua q.s. ad solutionem pro 1 ml. - gemäss der anthroposophischen menschen- und naturerkenntnis als zusatzbehandlung zur verbesserung der lebensqualität und eventuell des krankheitsverlaufes bei malignen geschwulstkrankheiten, auch mit begleitenden störungen der blutbildenden organe, bei benignen geschwulstkrankheiten und nach operationen von malignen geschwülsten - antroposofici

שווייץ - איטלקית - Swissmedic (Swiss Agency for Therapeutic Products)

iscador ag - viscum album (quercia) fresco - soluzione iniettabile (s. c.) - extractum aquosum liquidum fermentatum 5 mg ex viscum album (quercus) recens 1 mg corresp., lectina ex visco 75 ng, natrii chloridum, aqua q.s. ad solutionem pro 1 ml. - gemäss der anthroposophischen menschen- und naturerkenntnis als zusatzbehandlung zur verbesserung der lebensqualität und eventuell des krankheitsverlaufes bei malignen geschwulstkrankheiten, auch mit begleitenden störungen der blutbildenden organe, bei benignen geschwulstkrankheiten und nach operationen von malignen geschwülsten - antroposofici

שווייץ - איטלקית - Swissmedic (Swiss Agency for Therapeutic Products)

iscador ag - viscum album (quercia) fresco - soluzione iniettabile (s. c.) - extractum aquosum liquidum fermentatum 10 mg ex viscum album (quercus) recens 2 mg corresp., lectina ex visco 150 ng, natrii chloridum, aqua q.s. ad solutionem pro 1 ml. - gemäss der anthroposophischen menschen- und naturerkenntnis als zusatzbehandlung zur verbesserung der lebensqualität und eventuell des krankheitsverlaufes bei malignen geschwulstkrankheiten, auch mit begleitenden störungen der blutbildenden organe, bei benignen geschwulstkrankheiten und nach operationen von malignen geschwülsten - antroposofici